Please login to the form below

Not currently logged in
Email:
Password:

Lutathera

This page shows the latest Lutathera news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

The company will also highlight its radioligand portfolio, currently headed by Lutathera (. 177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, which was recently bolstered by the $2.1bn acquisition of

Latest news

  • Novartis buys cancer specialist Endocyte for $2.1bn

    Novartis wants to merge the company with a newly-formed subsidiary that will focus on radiopharmaceutical drugs for cancer, with Endocyte’s portfolio blended with in-house assets such as Lutathera (. ... Lutathera brought in $56m as it continues to

  • AAA board presses go on $3.9bn Novartis takeover AAA board presses go on $3.9bn Novartis takeover

    With the acquisition, Novartis is aiming to add AAA’s Lutathera (Lutetium Lu177 dotatate) for treating gastroenteropancreatic neuroendocrine tumours (NET) – approved in the EU and heading for an FDA decision towards

  • Novartis to buy French radiopharma specialist AAA for $3.9bn Novartis to buy French radiopharma specialist AAA for $3.9bn

    The Swiss pharma giant said this morning that the deal would help strengthen its cancer therapy businesses, adding an approved radiopharmaceutical drug - Lutathera (177Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours

  • AAA’s orphan drug Lutathera wins EU green light AAA’s orphan drug Lutathera wins EU green light

    AAA’ s orphan drug Lutathera wins EU green light. The first-in-class drug treats adults with GEP-NET. ... LAR. Buono added: “We will continue to work closely with the respective health authorities in each country to make Lutathera widely available.”

  • CHMP backs three immuno-oncology drugs for solid tumours CHMP backs three immuno-oncology drugs for solid tumours

    Advanced Accelerator Applications secured a recommendation for Lutathera (lutetium [177Lu] oxodotreotide) - for the treatment of gastro-entero-pancreatic neuroendocrine tumours - and Ipsen got the nod for Xermelo (telotristat ethyl) as a

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics